Global Targeted Protein Degradation Market (2021 to 2030) - by Type of Protein Degrader, Therapeutic Areas, Route of Administration, Key Contributing Technologies and Key Geographies
13 juil. 2021 05h18 HE
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route...
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
07 juin 2021 17h19 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
03 juin 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
02 juin 2021 07h00 HE
|
Nurix Therapeutics, Inc.
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
21 mai 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Arvinas to Present at the UBS Global Healthcare Virtual Conference
20 mai 2021 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
11 mai 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of...
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
04 mai 2021 14h52 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
04 mai 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
13 avr. 2021 16h01 HE
|
Nurix Therapeutics, Inc.
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...